National Medical Products Administration

China's drug regulator approved a novel, globally trialled medicine ahead of the United States, Japan, and Europe, marking a historic breakthrough as the country prioritizes biopharmaceuticals as a growth engine. The drug was filed for market approval in multiple countries, with China being the first to approve it.

China's drug regulator approved a novel medicine ahead of the United States, Japan, and Europe, marking a historic breakthrough in biopharmaceuticals. The drug was filed for approval in multiple countries, with China being the first to approve it.

China's drug industry is shifting focus to AI-powered drug candidates to drive future deals, following record US$110 billion in cross-border transactions for innovative drugs in the first half of 2026. China accounts for 30% of globally developed new drugs, ranking second worldwide.

China's cross-border deals for innovative drugs reached $110 billion in H1 2026, with the industry now focusing on AI-powered candidates to drive future transactions. China holds 30% of globally developed new drugs, ranking second worldwide, according to Lan Gongtao from the National Medical Products Administration.

Clinical drug trial registrations in China reached a record 5,215 in 2025, more than double the 2020 figure, with 57.5% of trials focused on new drugs, according to a report by the National Medical Products Administration. The surge in trials highlights China’s growing pipeline of novel drug candidates and has raised US security concerns.

China's National Medical Products Administration (NMPA) has approved 19 innovative drugs this year, with 15 developed by domestic companies, highlighting the country's biotech boom. Notable examples include sonrotoclax, a cancer drug developed by BeOne for treating adult blood cancers.

China’s National Medical Products Administration (NMPA) approved 19 innovative drugs in 2024, with 15 developed by domestic companies, highlighting the country’s biotech growth. Notable approvals include sonrotoclax by BeOne for treating adult blood cancers, as the regulator streamlines its approval process.